Allorion Therapeutics

The page lists news about Allorion Therapeutics by year, including Avenzo Therapeutics’ 2025 FDA clearance for AVZO-023 and its 2024 global license of AVZO-021.

The careers page lists a closed Head of Medicinal Chemistry position in Natick, Massachusetts.

The team includes CEO Peter Ding, Chief Scientific Officer Fang Li, Ph.D., and scientific advisers Nathanael Gray, Ph.D., Professor at Stanford University, and Pasi Jänne, M.D., Ph.D., Professor at Dana Farber.

The page lists contact addresses for Allorion Therapeutics in Natick, MA, and Guangzhou, China.

Pioneering Precision in Healthcare. The Next-Generation Targeted Drugs for Human Diseases

Avenzo Therapeutics announces FDA clearance of its investigational new drug application for AVZO-023 (ARTS-023). The compound is a novel, orally bioavailable CDK4-selective inhibitor from a partnership with Allorion and has high selectivity over CDK6. Avenzo describes it as a potential best-in-class candidate for HR+/HER2− breast cancer.

May 2025 · Avenzo TherapeuticsNews article

Avenzo Therapeutics obtains a global license from Allorion Therapeutics for ARTS-021, also known as AVZO-021, a clinical-stage CDK2 inhibitor. The inhibitor is described as highly potent, selective, and isoform-specific, and is being developed for HR+/HER2- breast cancer and CCNE1-amplified cancers. The FDA cleared its IND in May 2023, and the first patient was dosed in a Phase 1/2 trial in October 2023.

Jan 2024 · PR NewswireNews article

Allorion Therapeutics grants AstraZeneca an exclusive option and global license for its novel preclinical-stage EGFR L858R allosteric inhibitor program. The program targets activating EGFR L858R mutations through a non-conventional precision approach, with potential for combination with Tagrisso and to address resistance.

Jan 2024 · PR NewswireNews article

Allorion Therapeutics doses the first patient in a Phase 1/2 study of ARTS-021, its CDK2 inhibitor, for advanced or metastatic solid tumors. The open-label first-in-human trial, NCT05867251, is being conducted in the United States and evaluates safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy. The study proceeds under an investigational new drug application cleared by the FDA in May 2023.

Oct 2023 · PR NewswireNews article